|
|
|
Volumn 19, Issue 1, 2001, Pages
|
|
Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist
a
a
a
|
|
Author keywords
Clinical pharmacology studies; Clinical trials; Dose response; Olmesartan medoxomil
|
|
Indexed keywords
ANGIOTENSIN 1 RECEPTOR ANTAGONIST;
ANTIHYPERTENSIVE AGENT;
OLMESARTAN;
PLACEBO;
UNCLASSIFIED DRUG;
ADULT;
BLOOD PRESSURE MONITORING;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CROSSOVER PROCEDURE;
DOSE RESPONSE;
DOUBLE BLIND PROCEDURE;
DRUG SCREENING;
HUMAN;
HUMAN EXPERIMENT;
MALE;
MODEL;
NORMAL HUMAN;
PHARMACODYNAMICS;
PHASE 2 CLINICAL TRIAL;
PRESSOR RESPONSE;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;
REVIEW;
SODIUM DEPLETION;
ADULT;
ANGIOTENSIN I;
ANTIHYPERTENSIVE AGENTS;
BLOOD PRESSURE;
BLOOD PRESSURE MONITORING, AMBULATORY;
CIRCADIAN RHYTHM;
CROSS-OVER STUDIES;
DIET, SODIUM-RESTRICTED;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DOUBLE-BLIND METHOD;
DRUG ADMINISTRATION SCHEDULE;
HUMANS;
HYPERTENSION;
IMIDAZOLES;
MALE;
MULTICENTER STUDIES;
RANDOMIZED CONTROLLED TRIALS;
RECEPTOR, ANGIOTENSIN, TYPE 1;
RECEPTORS, ANGIOTENSIN;
SEVERITY OF ILLNESS INDEX;
TETRAZOLES;
|
|
EID: 0034951899
PISSN: 09521178
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (29)
|
|
References (11)
|
